There have been no published studies to date demonstrating safe and effective transition to oral bosentan in patients with persisting significant PAH previously receiving continuous prostacyclin ...
Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused prostacyclins.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback